company background image
QURE

uniQureNasdaqGS:QURE Stock Report

Market Cap

US$1.6b

7D

-8.3%

1Y

-9.6%

Updated

25 Sep, 2021

Data

Company Financials +
QURE fundamental analysis
Snowflake Score
Valuation5/6
Future Growth0/6
Past Performance4/6
Financial Health6/6
Dividends0/6

QURE Overview

uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases.

uniQure Competitors

Price History & Performance

Summary of all time highs, changes and price drops for uniQure
Historical stock prices
Current Share PriceUS$33.77
52 Week HighUS$25.80
52 Week LowUS$52.19
Beta1.21
1 Month Change17.26%
3 Month Change9.15%
1 Year Change-9.59%
3 Year Change-7.20%
5 Year Change341.44%
Change since IPO131.14%

Recent News & Updates

Shareholder Returns

QUREUS BiotechsUS Market
7D-8.3%-2.3%0.1%
1Y-9.6%26.1%35.3%

Return vs Industry: QURE underperformed the US Biotechs industry which returned 31% over the past year.

Return vs Market: QURE underperformed the US Market which returned 37.5% over the past year.

Price Volatility

Is QURE's price volatile compared to industry and market?
QURE volatility
QURE Beta1.21
Industry Beta1.03
Market Beta1

Stable Share Price: QURE is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: QURE's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1998332Matt Kapustahttps://www.uniqure.com

uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington’s disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-180 for the treatment of hemophilia A; AMT-190, an IV-administered adeno-associated virus (AAV) 5-based gene therapy for the treatment of Fabry disease; and AMT-150, a one-time, intrathecally-administered, AAV gene therapy for treating spinocerebellar ataxia type 3. The company has collaboration and license agreements with Bristol Myers-Squibb Company; Gen-X; and Synpromics Limited.

uniQure Fundamentals Summary

How do uniQure's earnings and revenue compare to its market cap?
QURE fundamental statistics
Market CapUS$1.56b
Earnings (TTM)US$303.44m
Revenue (TTM)US$500.20m

5.1x

P/E Ratio

3.1x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
QURE income statement (TTM)
RevenueUS$500.20m
Cost of RevenueUS$155.94m
Gross ProfitUS$344.26m
ExpensesUS$40.82m
EarningsUS$303.44m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)6.58
Gross Margin68.82%
Net Profit Margin60.66%
Debt/Equity Ratio11.2%

How did QURE perform over the long term?

See historical performance and comparison

Valuation

Is uniQure undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: QURE ($33.77) is trading below our estimate of fair value ($70.95)

Significantly Below Fair Value: QURE is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: QURE is good value based on its PE Ratio (5.1x) compared to the US Biotechs industry average (25.4x).

PE vs Market: QURE is good value based on its PE Ratio (5.1x) compared to the US market (17.9x).


Price to Earnings Growth Ratio

PEG Ratio: QURE's earnings are forecast to decline next year, so we can't calculate its PEG ratio.


Price to Book Ratio

PB vs Industry: QURE is good value based on its PB Ratio (2.5x) compared to the US Biotechs industry average (3.3x).


Future Growth

How is uniQure forecast to perform in the next 1 to 3 years based on estimates from 16 analysts?

-50.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: QURE's earnings are forecast to decline over the next 3 years (-50.8% per year).

Earnings vs Market: QURE's earnings are forecast to decline over the next 3 years (-50.8% per year).

High Growth Earnings: QURE's earnings are forecast to decline over the next 3 years.

Revenue vs Market: QURE's revenue is expected to decline over the next 3 years (-17.9% per year).

High Growth Revenue: QURE's revenue is forecast to decline over the next 3 years (-17.9% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: QURE is forecast to be unprofitable in 3 years.


Past Performance

How has uniQure performed over the past 5 years?

6.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: QURE has high quality earnings.

Growing Profit Margin: QURE became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: QURE has become profitable over the past 5 years, growing earnings by 6.3% per year.

Accelerating Growth: QURE has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: QURE has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).


Return on Equity

High ROE: QURE's Return on Equity (47.9%) is considered outstanding.


Financial Health

How is uniQure's financial position?


Financial Position Analysis

Short Term Liabilities: QURE's short term assets ($694.2M) exceed its short term liabilities ($46.1M).

Long Term Liabilities: QURE's short term assets ($694.2M) exceed its long term liabilities ($104.6M).


Debt to Equity History and Analysis

Debt Level: QURE's debt to equity ratio (11.2%) is considered satisfactory.

Reducing Debt: QURE's debt to equity ratio has reduced from 13.7% to 11.2% over the past 5 years.

Debt Coverage: QURE's debt is well covered by operating cash flow (428.5%).

Interest Coverage: QURE's interest payments on its debt are well covered by EBIT (56.8x coverage).


Balance Sheet


Dividend

What is uniQure current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate QURE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate QURE's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if QURE's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if QURE's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of QURE's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.0yrs

Average management tenure


CEO

Matt Kapusta (49 yo)

4.75yrs

Tenure

US$4,465,377

Compensation

Mr. Matthew Craig Kapusta, also known as Matt, has been the Chief Executive Officer of uniQure N.V. since December 19, 2016 and served as its Chief Financial Officer until June 15, 2021. Mr. Kapusta served...


CEO Compensation Analysis

Compensation vs Market: Matt's total compensation ($USD4.47M) is about average for companies of similar size in the US market ($USD3.67M).

Compensation vs Earnings: Matt's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: QURE's management team is not considered experienced ( 1 years average tenure), which suggests a new team.


Board Members

Experienced Board: QURE's board of directors are considered experienced (4.6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: QURE insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.1%.


Top Shareholders

Company Information

uniQure N.V.'s employee growth, exchange listings and data sources


Key Information

  • Name: uniQure N.V.
  • Ticker: QURE
  • Exchange: NasdaqGS
  • Founded: 1998
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$1.557b
  • Shares outstanding: 46.11m
  • Website: https://www.uniqure.com

Number of Employees


Location

  • uniQure N.V.
  • Paasheuvelweg 25a
  • Amsterdam
  • Noord-Holland
  • 1105 BP
  • Netherlands

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/09/25 02:23
End of Day Share Price2021/09/24 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.